What is the name of the cyclic RGD-based tracer introduced by GE Healthcare?

The cyclic RGD-based tracer introduced by GE Healthcare is indeed 18F-AH111585, also known as Flucidatide. This tracer was specifically designed to target integrins, which play a critical role in cell adhesion and are often overexpressed in tumors. The cyclic RGD (arginine-glycine-aspartic acid) motif allows for targeted imaging of cancerous tissues that express these integrins, making it valuable in oncology for visualizing tumor involvement and monitoring treatment response.

The use of a fluorinated compound like 18F in the tracer enhances its imaging capabilities through positron emission tomography (PET), as fluorine-18 has favorable half-life characteristics and is well-suited for metabolic imaging. Flucidatide’s selectivity for integrins can aid in distinguishing aggressive tumors from benign conditions, contributing to more personalized treatment planning.

In contrast, the other choices provided do not represent cyclic RGD-based tracers. While they may be useful in various imaging applications, they do not have the same specific targeting mechanism or clinical purpose as Flucidatide.